RESOURCE FOR NONHUMAN PRIMATE CELL DEPLETING ANTIBODIES

非人灵长类细胞耗竭抗体的资源

• 批准号: 6529931
• 负责人: KEITH A. REIMANN
• 金额: $ 67.33万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6529931
• 关键词: DNA directed RNA polymerase; RNA binding protein; X ray crystallography; adduct; bioengineering /biomedical engineering; bioimaging /biomedical imaging; biomedical equipment development; biomedical equipment resource; biomedical facility; galactosyltransferases; nuclear magnetic resonance spectroscopy; protein structure function

DESCRIPTION (Adapted from the applicant's abstract): The in vivo administration of monoclonal antibodies (mAbs) that bind to cell-surface glycoproteins can block the actions mediated by those molecules, deliver stimulatory signals through the bound molecules, or result in depletion of the targeted cell population. This approach has been extremely useful to study immunopathogenic events in rodent models. Emerging recombinant antibody technologies now can provide chimerized, humanized and primatized antibodies, making similar experimental approaches feasible in NHP models. Among NIH investigators funded through eight NIH Institutes or Centers, the applicants documented a need for access to antibodies capable of depleting subsets of lymphocytes. The generation of these recombinant antibodies as research tools can be best realized by creating a resource for identifying and developing mAbs relevant to the NHP models and for optimizing the experimental protocols for their use. Furthermore, maximizing accessibility to these unique reagents will require manufacturing and distributing large quantities of highly purified mAbs appropriate for use in NHPs. In this application the investigators propose to develop a resource that facilitates the use of mAbs as research reagents in NHPs. Specificically, the applicants will establish a resource to: 1) Identify, produce, test and distribute existing mAbs that will serve as relevant research tools in NHP models; 2) Optimize the use of these mAb research reagents and characterize the models in which they are used; 3) Develop second generation recombinant antibodies that have longer durations of action using emerging molecular techniques.

描述（改编自申请人的摘要）：体内 与细胞表面结合的单克隆抗体（mAb）的给药 糖蛋白可以阻止由这些分子介导的作用，传递 通过结合分子的刺激信号，或导致耗尽 目标细胞群。 这种方法非常有用 啮齿动物模型中的免疫致病事件。 新兴的重组抗体 现在，技术可以提供嵌合，人性化和原始化抗体， 在NHP模型中使类似的实验方法可行。 在NIH中 通过八个NIH机构或中心资助的调查人员，申请人 记录了需要访问能够耗尽子集子集的抗体的需求 淋巴细胞。 这些重组抗体作为研究工具的产生 可以通过创建用于识别和开发的资源来最好地实现 与NHP模型相关的mAB和用于优化实验协议 为了使用。 此外，最大化这些独特试剂的可及性 将需要制造和分发大量高度 纯化的mAb适合在NHP中使用。 在此应用程序中 调查人员建议开发一种有助于使用mAB的资源 作为NHP的研究试剂。 从具体而言，申请人将建立一个资源：1）确定， 生产，测试和分发现有的mAB，将作为相关 NHP模型中的研究工具； 2）优化这些mAB研究的使用 试剂并表征使用它们的模型； 3）发展第二 生成重组抗体的作用持续时间更长 新兴分子技术。